Events & Promotions
|
|
GMAT Club Daily Prep
Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.
Customized
for You
Track
Your Progress
Practice
Pays
Not interested in getting valuable practice questions and articles delivered to your email? No problem, unsubscribe here.
Apr 2610:00 AM EDT
-11:00 AM EDT
The Target Test Prep course represents a quantum leap forward in GMAT preparation, a radical reinterpretation of the way that students should study. Try before you buy with a 5-day, full-access trial of the course for FREE!
Apr 2711:00 AM EDT
-12:00 PM EDT
Prefer video-based learning? The Target Test Prep OnDemand course is a one-of-a-kind video masterclass featuring 400 hours of lecture-style teaching by Scott Woodbury-Stewart, founder of Target Test Prep and one of the most accomplished GMAT instructors
Apr 2808:00 AM PDT
-11:00 AM PDT
Whether you are just beginning your MBA journey or fine-tuning your path to a 700+ score, GMAT Day is designed to give you a competitive edge.
25 Mar 2025, 23:22
Kudos
Bookmarks
B
Be sure to select an answer first to save it in the Error Log before revealing the correct answer (OA)!
Difficulty:
35%
(medium)
Question Stats:
76% (01:56) correct
24%
(02:11)
wrong
based on 99
sessions
History
Date
Time
Result
Not Attempted Yet
A pharmaceutical company has developed a new drug, "VitaPlus," which clinical trials have shown to be highly effective in reducing the symptoms of a rare autoimmune disorder. The company plans to market VitaPlus aggressively, emphasizing its superior efficacy compared to existing treatments. However, a recent independent study, while confirming the drug's efficacy, also revealed a rare but serious side effect that occurred in 0.5% of the trial participants. This side effect was not observed in the company's initial trials. The company has decided to include information about this side effect in the drug's labeling but will not highlight it in their marketing campaigns.
Which of the following is the most serious challenge to the pharmaceutical company's strategy for marketing VitaPlus?
(A) The cost of VitaPlus is significantly higher than that of existing treatments for the same autoimmune disorder.
(B) Physicians may be hesitant to prescribe a drug with a known serious side effect, even if it is rare.
(C) The independent study that revealed the side effect received funding from a competing pharmaceutical company.
(D) Patients suffering from rare autoimmune disorders often have limited treatment options and are willing to tolerate some side effects.
(E) The company's marketing campaigns for other drugs have historically focused primarily on efficacy and downplayed potential side effects.
(A) While cost is a factor, the question focuses on the challenge to the marketing strategy given the side effect. Even with a high cost, strong physician endorsement could drive sales. (Irrelevant)
(B) directly addresses the core issue with the marketing strategy. If they are hesitant to prescribe VitaPlus due to the serious side effect, the company's aggressive marketing emphasizing efficacy will likely be undermined. (Lets keep it)
(C) This introduces a potential bias in the independent study, which could weaken the finding of the side effect. However, as it stands, the side effect is a known factor the company must address. ( Indirectly helps the marketing strategy, weakens the opposite study)
(D) This suggests that patients might be accepting of side effects, which could support the company's strategy, not challenge it. (Supports)
(E) This describes the company's past behavior, but doesn't necessarily present the most serious challenge to the current strategy for VitaPlus, especially given the newly discovered side effect. (Does'nt help in current situation, Extrapolation or irrelevant coorelation)
B is correct. Hope it helps.
Which of the following is the most serious challenge to the pharmaceutical company's strategy for marketing VitaPlus?
(A) The cost of VitaPlus is significantly higher than that of existing treatments for the same autoimmune disorder.
(B) Physicians may be hesitant to prescribe a drug with a known serious side effect, even if it is rare.
(C) The independent study that revealed the side effect received funding from a competing pharmaceutical company.
(D) Patients suffering from rare autoimmune disorders often have limited treatment options and are willing to tolerate some side effects.
(E) The company's marketing campaigns for other drugs have historically focused primarily on efficacy and downplayed potential side effects.
(A) While cost is a factor, the question focuses on the challenge to the marketing strategy given the side effect. Even with a high cost, strong physician endorsement could drive sales. (Irrelevant)
(B) directly addresses the core issue with the marketing strategy. If they are hesitant to prescribe VitaPlus due to the serious side effect, the company's aggressive marketing emphasizing efficacy will likely be undermined. (Lets keep it)
(C) This introduces a potential bias in the independent study, which could weaken the finding of the side effect. However, as it stands, the side effect is a known factor the company must address. ( Indirectly helps the marketing strategy, weakens the opposite study)
(D) This suggests that patients might be accepting of side effects, which could support the company's strategy, not challenge it. (Supports)
(E) This describes the company's past behavior, but doesn't necessarily present the most serious challenge to the current strategy for VitaPlus, especially given the newly discovered side effect. (Does'nt help in current situation, Extrapolation or irrelevant coorelation)
B is correct. Hope it helps.
07 Jan 2026, 13:48
Kudos
Bookmarks
Sketchitesh
Answer: B
The strategy is to market the drug while downplaying the side effect. B challenges this because doctors may hesitate to prescribe a drug with any serious side effect, even if it's rare.
Other options:
A: The cost doesn't directly challenge the marketing strategy.
C: Funding source of the study raises doubts but doesn’t change the fact that the side effect exists.
D: Patients may tolerate side effects, which strengthens the case for the drug rather than challenging it.
E: Past marketing strategies are irrelevant to the current issue with the side effect.
Moderators:
